ZWI-ZW25-301-BGB GEA
03 Jan 2023
Trial Summary
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers.
Acronym:
ZWI-ZW25-301-BGB GEA
ACTRN/NCT /ethics:
NCT02892123
Scientific title:
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Sponsor / Cooperative group:
Zymeworks Inc.
Trial & Patient Characteristics
| Cancer Type | HER2-expressing Cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Advanced |
| Anticipated Start Date | 2016-09-01 |
| Anticipated End Date | 2023-08-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alison Richards |
| Alison.Richards@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Dr Amitesh Roy |
| Recruitment Status | Recruiting |